Bradykinin

SKU: orb1296680

Description

Bradykinin is a nine-amino acid kinin peptide that acts as a potent inflammatory mediator, inducing vasodilation through the release of prostacyclin, nitric oxide, and EDHF. It is widely used in cardiovascular, inflammation, and pain research, both in vitro and in vivo, to study vascular permeability and receptor signaling pathways.

Research Area

Metabolism Research, Pharmacology & Drug Discovery, Protein Biochemistry

Key Properties

• CAS Number: 58-82-2
• MW: 1060.21
• Purity: >99.99% (May vary between batches)
• Formula: C₅₀H₇₃N₁₅O₁₁
• SMILES: N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O
• Target: Endogenous Metabolite,Bradykinin Receptor,Serine Protease
• Solubility: DMSO:10 mM;H2O:100 mg/mL (94.32 mM)

Bioactivity

• In Vivo:
  Application of 1 μM bradykinin to the ovary produces significant decreases in heart rate and mean arterial pressure. Application of 1 μM bradykinin to the ovary produces bradycardia and hypotension similar to the responses evoked when vagal innervation is intact in vagotomized animals. Vascular bradykinin can improve pancreatic microcirculation and hemorheology in rats with severe acute pancreatitis. The pancreatic microcirculatory blood flow volume and velocity in the vascular bradykinin treatment group increases gradually after 48 h. PI3K/Akt signaling pathway activation induced by bradykinin administration reduces the activity of GSK-3β and MAPK, and reduces NF-x03BA;B level in the nucleus, thereby inhibiting TF expression. Consistent with this, intraperitoneal injection of C57/BL6 mice with bradykinin also inhibits the thrombus formation induced by ligation of inferior vena cava.
• In Vitro:
  Bradykinin is a potent vasodilator peptide that exerts its vasodilatory action through stimulation of specific endothelial B2 receptors, thereby causing the release of prostacyclin, NO, and EDHF. Bradykinin has been reported to be involved in the progression of many types of cancer. Bradykinin treatment stimulates ERK1/2 activation and IL-6 production thereby contributing to the invasion and migration of colorectal cancer cells. . Exogenous bradykinin markedly inhibits TF expression in mRNA and protein level induced by LPS in a dose-dependent manner. The NO synthase antagonist L-NAME and PI3K inhibitor LY294002 dramatically abolish the inhibitory effects of bradykinin on tissue factor expression.

Storage & Handling

• Storage: keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Threonine proteases, Serine proteases, Ser/Thr Protease, Serine endopeptidases, Bradykinin, Bradykinin Receptor, BradykininReceptor, Inhibitor, EndogenousMetabolite, Endogenous Metabolite, inhibit

Compound Identifiers

PubChem CID

439201